Rigel Pharmaceuticals Inc. (RIGL) Financial Statements (2026 and earlier)

Company Profile

Business Address 611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:155,01277,32156,93358,206124,96757,327
Cash and cash equivalent40,58056,74632,78624,45918,89030,373
Short-term investments114,37520,57524,14733,747106,07726,954
Other undisclosed cash, cash equivalents, and short-term investments57     
Receivables51,76341,61530,55040,32015,47215,973
Inventory, net of allowances, customer advances and progress billings11,5066,0025,5229,1186,6161,638
Inventory11,5066,0025,5229,1186,6161,638
Advances on inventory purchases  3,800 800 4,000
Other current assets5,207     
Other undisclosed current assets16,6786,3656,2617,4597,41210,045
Total current assets:240,166135,10399,266115,903154,46788,983
Noncurrent Assets
Operating lease, right-of-use asset9202468611,9309,70317,895
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization  921658572,1842,676
Intangible asset, including goodwill, after accumulated amortization24,74827,10013,87814,949  
Intangible asset, excluding goodwill, after accumulated amortization24,74827,10013,87814,949  
Deferred income tax assets245,852     
Other noncurrent assets1,9081,4353,055640974824
Total noncurrent assets:273,42828,87317,95918,37612,86121,395
TOTAL ASSETS:513,594163,976117,225134,279167,328110,378
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:30,57123,87421,15237,85912,69111,014
Interest and dividends payable✕✕✕✕✕387272
Taxes payable✕✕✕✕✕605 
Employee-related liabilities✕✕✕✕8,866  
Accounts payable7,1913,3397,14222,508  
Accrued liabilities23,38020,53514,0106,4853,5803,661
Other undisclosed accounts payable and accrued liabilities     8,1197,081
Deferred revenue  1,3551,3551,3692,5963,018
Debt29,8127,2727,229  8,621
Other liabilities 11,466 3,6424,99713,506 
Other undisclosed current liabilities27,38830,79819,88920,98634,76118,188
Total current liabilities:99,23763,29953,26765,21163,55440,841
Noncurrent Liabilities
Long-term debt and lease obligation22,48252,40852,37339,44820,67330,466
Long-term debt, excluding current maturities22,48252,40852,37339,44819,91419,815
Liabilities, other than long-term debt39539,98140,22943,23652,7275,045
Other liabilities  39,98139,94442,26452,7275,045
Operating lease, liability395 28597275910,651
Other undisclosed noncurrent liabilities  5,000    
Total noncurrent liabilities:22,87797,38992,60282,68473,40035,511
Total liabilities:122,114160,688145,869147,895136,95476,352
Equity
Equity, attributable to parent391,4803,288(28,644)(13,616)30,37434,026
Common stock1818175174172169
Additional paid in capital1,414,3221,393,3251,378,7231,368,8221,354,1901,339,833
Accumulated other comprehensive income (loss)181108(153)(102)(4)
Accumulated deficit(1,023,041)(1,390,065)(1,407,550)(1,382,459)(1,323,886)(1,305,972)
Total equity:391,4803,288(28,644)(13,616)30,37434,026
TOTAL LIABILITIES AND EQUITY:513,594163,976117,225134,279167,328110,378

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues294,282179,278116,882120,242149,236108,621
Cost of revenue
(Cost of Product and Service Sold)
(19,621)(18,647)(7,110)(1,749)(1,083)(895)
Gross profit:274,661160,631109,772118,493148,153107,726
Operating expenses(149,195)(136,439)(130,263)(174,043)(160,649)(136,699)
Operating income (loss):125,46624,192(20,491)(55,550)(12,496)(28,973)
Nonoperating income
(Investment Income, Nonoperating)
3,6812,0922,27268447704
Interest and debt expense(7,320)(7,918)(6,872)(3,707)(4,860)(1,353)
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Income (loss) from continuing operations before equity method investments, income taxes:121,82718,366(25,091)(58,573)(17,309)(29,622)
Other undisclosed income from continuing operations before income taxes      
Income (loss) from continuing operations before income taxes:121,82718,366(25,091)(58,573)(17,309)(29,622)
Income tax expense (benefit)245,197(881)  (605) 
Income (loss) from continuing operations:367,02417,485(25,091)(58,573)(17,914)(29,622)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(17,914)(29,622)
Other undisclosed net loss      (122)
Net income (loss) available to common stockholders, diluted:367,02417,485(25,091)(58,573)(17,914)(29,744)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):367,02417,485(25,091)(58,573)(17,914)(29,744)
Comprehensive income (loss):367,02417,485(25,091)(58,573)(17,914)(29,744)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1712161(51)(98)(27)
Comprehensive income (loss), net of tax, attributable to parent:367,19517,487(24,930)(58,624)(18,012)(29,771)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: